Federal Draft Guidance Focuses on Alternative Methods to Animal Testing

A recent FDA draft guidance encourages drug developers to reduce reliance on animal testing by adopting alternative methods known as new approach methodologies. These include technologies such as cell-based studies, organ-on-chip models, and computer simulations that are designed to better predict human responses to drugs. The guidance is part of a broader effort to modernize drug development and move away from animal testing as the standard approach. It outlines principles for validating these alternative methods to ensure they are scientifically reliable, relevant to human biology, and appropriate for regulatory use.

Regulators note that traditional animal models do not always accurately predict human outcomes, while newer technologies may improve safety, efficiency, and ethical standards. Although animal testing may still be required in certain cases, the FDA encourages collaboration to expand the use of alternatives, which could accelerate development timelines and improve results for both patients and animals.